332 related articles for article (PubMed ID: 33590292)
1. [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].
Köhl U; Abken H
Internist (Berl); 2021 Apr; 62(4):449-457. PubMed ID: 33590292
[TBL] [Abstract][Full Text] [Related]
2. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
3. Impact of Manufacturing Procedures on CAR T Cell Functionality.
Watanabe N; Mo F; McKenna MK
Front Immunol; 2022; 13():876339. PubMed ID: 35493513
[TBL] [Abstract][Full Text] [Related]
4. What CAR Will Win the CD19 Race?
Quintás-Cardama A
Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
[TBL] [Abstract][Full Text] [Related]
5. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
[TBL] [Abstract][Full Text] [Related]
7. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
9. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
10. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
[TBL] [Abstract][Full Text] [Related]
13. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.
Labbé RP; Vessillier S; Rafiq QA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452392
[TBL] [Abstract][Full Text] [Related]
16. Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform.
Trainor N; Purpura KA; Middleton K; Fargo K; Hails L; Vicentini-Hogan M; McRobie C; Daniels R; Densham P; Gardin P; Fouks M; Brayer H; Malka RG; Rodin A; Ogen T; Besser MJ; Smith T; Leonard D; Bryan A
Cytotherapy; 2023 Dec; 25(12):1349-1360. PubMed ID: 37690020
[TBL] [Abstract][Full Text] [Related]
17. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
[TBL] [Abstract][Full Text] [Related]
18. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
19. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.
Subklewe M; von Bergwelt-Baildon M; Humpe A
Transfus Med Hemother; 2019 Feb; 46(1):15-24. PubMed ID: 31244578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
